Why choose Biocytogen's fully human VHH assets?

Biocytogen developed a fully human TCR-mimic (TCRm) antibody discovery platform using our proprietary RenTCR-mimic^™ mice.

• Harnessing a proprietary immunization protocol, we can directly obtain diverse peptide/HLA targeting antibodies for downstream screening.
• These antibodies have high specificity and minimal off-target toxicity, and compared with endogenous TCRs, the affinity of TCRm antibodies to their target is higher, minimizing the chance of tumor immune escape.
• In addition to this, our innovative mouse model and in vivo/in vitro pharmacology platform simplify the identification of preclinical candidates (PCC).

Our TCR-mimic assets currently open for partnership

Selected assets overview

Contact us today for data packages and licensing/co-development opportunities!

WT1/HLA-A02×CD3×4-1BB trispecific T cell engager

WT1-TOPAbody highlights

• WT1 is an intracellular protein aberrantly presented in multiple hematological malignancies and solid tumors.
• WT1-TOPAbody demonstrated efficacy and advantage in vitro and in vivo.
  • High affinity and specificity ​against WT1/HLA-A02
  • Target-dependent and long-lasting T cell activation and proliferation.
  • Dose-dependent anti-tumor efficacy.
  • Minimal cytokine release in the absence of the target.
• IND expected in 2H2025.

Strong on-target T cell proliferation

Dose-dependent anti-tumor efficacy.

64 specific clones were screened out of 87 antibody sequences

Identification of specific WT1/HLA-A0201 antibodies without off- target bindings

Fully human TCRm antibodies from HLA/RenMab are highly diverse and with high affinity

In vivo efficacy of WT1/HLA x CD3 engager

KRAS G12V_7-16/HLA-A03

KRAS G12V_7-16/HLA-A03 highlights

• KRAS G12V7-16/HLA-A03 TCRm antibodies.
  • Specific binding to the G12V mutation and the HLA-A03 allele
  • High affinity
  • No binding to potential off-target peptides
• Bispecific T cell engager:
  KRAS G12V_7-16/HLA-A03 x CD3
  • Specific in vitro cytotoxic activity

No binding to potential off-target peptides

Protein	Peptide
KRAS G12V7-16	VVVGAVGVGK
MRAS	VVVGDGGVGK
ERAS	VVVGASGVGK
Rab-7b	IIVGAIGVGK
RhoJ	VVVGDGAVGK
mRho GTPase2	KVVGARGVGK

The bispecific anti-KRAS G12V_7-16/HLA-A03 x CD3nano T cell engager demonstrated specific cytotoxic activity

NY-ESO-1/HLA-A02

NY-ESO-1/HLA-A02 highlights

• NY-ESO-1/HLA-A02 TCRm antibodies.
  • High specificity and affinity
  • Diversified binding pattern and low off-target risk
• TCRm-T cell therapy
  • Specific killing of target cells in vitro
  • Rapid and obvious clearance of NY-ESO-1+/HLA-A02+ tumors in vivo

Potent anti-tumor activity of NY-ESO-1/HLA-A02 TCRm-T